Bizarre Patents
An electrified table cloth for preventing crawling insects from gaining access to the consumer's food or drink.
PatentStorm News
Make the Most of PatentStorm
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest patents by subscribing to an RSS feed.
Got questions? Ask a Patent Expert!
Registered users: Manage your profile, comments and alerts.
| Number | Title | Issue Date |
| 7659378 | Hepatocyte growth factor (HGF) binding antibody The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic a... | 02/09/2010 |
| 7655763 | Neutralizing antibodies against GDF-8 and uses therefor The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), in particular human antibodies, and antibody fragments, including those that inhibit GDF-8 activity in vitro and/or in vivo. The disclosure also provides methods for diagno... | 02/02/2010 |
| 7635760 | Anti-myostatin antibodies A neutralizing epitope is identified within amino acids 40-64 of the mature form of human myostatin. Antibodies that bind this epitope with high affinity preferentially bind GDF-8 over GDF-11 and may be chimeric, humanized or fully human antibodies, immunoconjugates... | 12/22/2009 |
| 7632926 | Humanized monoclonal antibodies to hepatocyte growth factor The present invention is directed toward a humanized neutralizing monoclonal antibody to hepatocyte growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient. ... | 12/15/2009 |
| 7608694 | Antibody molecules having specificity for human IL-1β The invention relates to an antibody molecule having specificity for antigenic determinants of IL-1β, therapeutic uses of the antibody molecule and methods for producing said antibody molecule. ... | 10/27/2009 |
| 7534870 | Stable pharmaceutical composition comprising erythropoietin The present invention provides a new stable pharmaceutical composition of erythropoietin (EPO) that is stabilized with a combination of a poloxamer polyol and a polyhydric alcohol. ... | 05/19/2009 |
| 7504485 | Human antibodies that bind human IL-12 Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can... | 03/17/2009 |
| 7491804 | DNA dependent protein kinase catalytic subunit phosphorylation sites and antibodies thereto The identification and use of two major DNA-PKcs autophosphorylation sites. Threonine (T) 2609 and Serine (S) 2056, including antibodies specific for phosphorylated T2609 and 52056. Peptides and polynucleotides encoding same, that feature these two sites of phosphor... | 02/17/2009 |
| 7446181 | Antibodies that bind human Dickkopf-1 proteins The invention relates to antibodies and immunologically active portions thereof that selectively bind a human Dickkopf-1 (Dkk-1) or Dkk-1-related polypeptide, and to compositions that contain such antibodies and/or immunologically active portions. ... | 11/04/2008 |
| 7435799 | TNF-α binding molecules The present invention relates to TNF-α binding molecules and nucleic acid sequences encoding TNF-α binding molecules. In particular, the present invention relates to TNF-α binding molecules with a high binding affinity, a high association rate, a low dissociation... | 10/14/2008 |
| 7435800 | Antibodies to interleukin-20 and method for inhibiting interleukin-20 induced cell proliferation Antibody to human IL-20 protein, a method for generation thereof and cells producing this antibody are disclosed. The antibody of the present invention has specificity to neutralizing hIL-20W-induced CPAE proliferation activity, and is useful for treating IL-20-indu... | 10/14/2008 |
| 7432360 | Multi-dose erythropoietin formulations The present invention is directed to multi-dose erythropoietin formulations for parenteral administrations. The formulations contain one or more of the following preservatives benzethonium chloride, phenoxyethanol and phenylethyl alcohol. ... | 10/07/2008 |
| 7431927 | TNFα-neutralizing antibodies The invention provides monoclonal antibodies that neutralize TNFα activity. The monoclonal antibodies may be rabbit monoclonal antibodies or monoclonal antibodies having CDR regions derived from those rabbit monoclonal antibodies. In certain embodiments, the monocl... | 10/07/2008 |
| 7427471 | Modified “S” antibodies The invention relates to the field of antibodies, and particularly to modified antibodies, methods of preparing modified antibodies and uses thereof. More particularly, the invention relates to the preparation of more active IgG antibodies by the addition of an extr... | 09/23/2008 |
| 7425330 | Methods of inhibiting TNFα activity in the blood of a patient Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and c... | 09/16/2008 |
| 7423129 | Antibodies to human eotaxin The invention relates to isolated and/or recombinant nucleic acids which encode a human chemotactic cytokine designated human eotaxin, and to isolated and/or recombinant human eotaxin proteins or polypeptides, including synthetic polypeptides. The invention further ... | 09/09/2008 |
| 7416729 | Methods of treating rheumatoid arthritis with anti-TNF antibodies Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and c... | 08/26/2008 |
| 7411049 | Hybridoma cell lines and monoclonal antibodies recognizing Prox1 Monoclonal antibodies to Prox1 of vertebrates (pfam05044.5; NM_002763.3) and two continuous cell lines for their production are disclosed. These antibodies are particularly useful in immunoassays to detect the presence of Prox1 protein in vertebrate tissues and cell... | 08/12/2008 |
| 7405277 | Antibodies against monocyte chemotactic proteins The invention provides antibodies that bind to a plurality of β-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides cells producing the antibodies, and methods of making and using the same. ... | 07/29/2008 |
| 7404955 | Methods of inhibiting or neutralizing TNFα in patients with tissue injury Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and c... | 07/29/2008 |
| 7405274 | Connective tissue growth factor antibodies The present invention relates to antibodies that bind to CTGF. The antibodies are particularly directed to regions of CTGF involved in biological activities associated with fibrosis. The invention also relates to methods of using the antibodies to treat disorders as... | 07/29/2008 |
| 7402662 | Antibody molecules specific to human tumor necrosis factor alpha There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNFα. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA ... | 07/22/2008 |
| 7396911 | Chimeric polypeptides containing chemokine domains This invention provides a chimeric DNA molecule comprising a sequence encoding a chemokine polypeptide covalently attached to a heterologous polypeptide, the encoded chimeric polypeptide, and uses thereof. ... | 07/08/2008 |
| 7390490 | Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine There are provided uses of an antibody directed to CX3CR1 and fractalkine. Killer lymphocytes can be readily identified, eliminated and separated by using an anti-CX3CR1 antibody. Further, there can be provided an antibody drug for suppressing chemotaxis and cytotox... | 06/24/2008 |
| 7390491 | Agents comprising midkine or an inhibitor thereof as active ingredient Midkine (MK), which is a retinoic acid-inducible heparin-binding growth factor, enhances neutrophilic migration and exists in an inflammatory state at a high concentration. The midkine or its inhibitors can be used for treating neutrophilic functional disorders or i... | 06/24/2008 |
| 7387776 | Human monoclonal antibodies against CD30 Isolated human monoclonal antibodies which bind to CD30 (e.g., human CD30) are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by underg... | 06/17/2008 |
| 7381801 | Chimerized GM-CSF antibodies Chimeric antibodies, as well as fusion proteins which comprise chimeric antibodies, are disclosed. The antibodies bind to GM-CSF, CD-30, and G250 antigen. The fusion proteins include biologically active portions of tumor necrosis factor, or full length tumor necrosi... | 06/03/2008 |
| 7374761 | Recombinant A2-specific TNFα-specific antibodies Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and c... | 05/20/2008 |
| 7371383 | Recombinant anti-interleukin-9 antibodies The application describes neutralizing chimeric and humanized anti-human IL-9 antibodies, and the use thereof to identify neutralizing epitopes on human IL-9 and as medicaments to prevent and treat asthma, bronchial hyperresponsiveness, atopic allergy, and other rel... | 05/13/2008 |
| 7371825 | Anti-MCP-1 antibodies, compositions, methods and uses The present invention relates to at least one novel anti-MCP-1 antibodies, including isolated nucleic acids that encode at least one anti-MCP-1 antibody, MCP-1, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including the... | 05/13/2008 |
| 7371377 | Antibodies to polypeptides homologous to VEGF and BMP1 The present invention involves the identification and preparation of vascular endothelial growth factor-E (VEGF-E). VEGF-E is a novel polypeptide related to vascular endothelial growth factor (VEGF) and bone morphogenetic protein 1. VEGF-E has homology to VEGF inclu... | 05/13/2008 |
| 7371826 | Polypeptide variants with altered effector function The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc reg... | 05/13/2008 |
| 7368111 | Human antibodies specific for TGFβ2 Specific binding members comprising human antibody antigen binding domains specific for human transforming growth factor beta (TGFβ) bind specifically isoforms TGFβ2 and TGFβ1 or both, preferentially compared with TGFβ3. Specific binding members may be isolated ... | 05/06/2008 |
| 7364865 | Antibodies to myeloid progenitor inhibitory factor-1 (MPIF-1) There are disclosed therapeutic compositions and methods using isolated nucleic acid molecules encoding a human myeloid progenitor inhibitory factor-1 (MPIF-1) polypeptide (previously termed MIP-3 and chemokine β8 (CKβ8 or ckb-8)); a human monocyte-colony inhibito... | 04/29/2008 |
| 7361474 | Serum macrophage migration inhibitory factor (MIF) as marker for prostate cancer The present invention provides methods for detecting, diagnosing or prognosticating prostate cancer by measuring the levels of macrophage migration inhibitory factor (MIF) in the serum of an individual. The assay for MIF can be an immunoassay, such as ELISA, or a nu... | 04/22/2008 |
| 7354584 | Recombinant IL-9 antibodies The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and compositions preventing, treating, managing, and/or ameliorating diseases... | 04/08/2008 |
| 7355014 | Interferon-γ inducing polypeptide, pharmaceutical composition thereof, monoclonal antibody thereto, and methods of use A human IFN-γ inducing polypeptide and its nucleotide sequence was isolated, purified and characterized. Pharmaceutical compositions containing this novel INF-γ inducing polypeptide or active fragments thereof are formulated and monoclonal antibodies are raised ag... | 04/08/2008 |
| 7342110 | Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved ver... | 03/11/2008 |
| 7335358 | Methods of treating psoriasis with anti-TNF antibodies Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and c... | 02/26/2008 |
| 7332289 | Method of purifying protein A method for removing contaminant DNA in a sample containing a physiologically active protein, which comprises the following steps: 1) converting the sample containing a physiologically active protein into a neutral aqueous solutio... | 02/19/2008 |